Skip to content

Rosuvastatin tablet bioequivalence

Bioequivalence study of the Rosuvastatin 20 mg tablets manufactured by Iran Hormone Pharmaceutical Company vs. Crestor® Tablets manufactured by AstraZeneca Pharmaceutical Company

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130313012810N87
Enrollment
24
Registered
2026-04-30
Start date
2025-07-16
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence study in healthy volunteers.

Interventions

Intervention 1: Intervention group1: In this group, volunteers are given a single oral dose of Rosuvastatin 20-mg capsules manufactured by Iran Hormone Pharmaceutical Company. In each period, 12 of 2

Sponsors

Iran hormone
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: The weight range of participating candidates should be between 60-100 kg Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose. Volunteers who have agreed to an informed consent form. All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw

Exclusion criteria

Exclusion criteria: History of allergic or adverse reaction to Rosuvastatin or any similar product Volunteers with blood pressure less than 90/60 mm Hg or higher than 140/90 mm Hg Individuals who have donated blood components within 2 months before taking the first dose of the drug. Individuals who donated blood components within 2 weeks prior to the first dose.

Design outcomes

Primary

MeasureTime frame
Plasma concentration of the drug. Timepoint: 18 sampling times included pre-dose (time 0) and at the following hours post-dose: 0.5? 1? 1.5? 2? 2.5? 3? 3.5? 4? 5? 6? 8? 10? 12? 24? 36? 48? and 72h. Method of measurement: Liquid Chromatography with tandem mass spectrometry (LC-MS-MS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Hamidi

Zanjan University of Medical Sciences

hamidi@hidapharma.com+98 24 3342 0651

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026